This NIH grant is offered to support R61/R33 applications focusing on health equity, drug costs, and access to novel or repurposed treatments for Alzheimer’s disease and related dementias (AD/ADRD). The purpose is to identify pharmacological treatment preferences among racial and ethnic minority individuals with AD/ADRD, assess existing cost barriers, and quantify related expenditures and health-related quality of life. The R61 phase supports rigorous stakeholder engagement with these minority groups to understand demand for new drugs. Successful projects will transition to an R33 phase for implementing robust modeling of costs and HRQoL, followed by dissemination of findings to address critical disparities in AD/ADRD care.
Opportunity ID: 338195
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-23-005 |
| Funding Opportunity Title: | Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 17, 2022 |
| Last Updated Date: | Feb 17, 2022 |
| Original Closing Date for Applications: | Jul 01, 2022 |
| Current Closing Date for Applications: | Jul 01, 2022 |
| Archive Date: | Aug 06, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses Native American tribal governments (Federally recognized) State governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) County governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.This FOA will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-005.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00272125 | Jun 01, 2022 | Jul 01, 2022 | View |
Package 1
Mandatory forms
338195 RR_SF424_5_0-5.0.pdf
338195 PHS398_CoverPageSupplement_5_0-5.0.pdf
338195 RR_OtherProjectInfo_1_4-1.4.pdf
338195 PerformanceSite_4_0-4.0.pdf
338195 RR_KeyPersonExpanded_4_0-4.0.pdf
338195 RR_Budget_3_0-3.0.pdf
338195 PHS398_ResearchPlan_4_0-4.0.pdf
338195 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
338195 RR_SubawardBudget30_3_0-3.0.pdf
338195 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
